Orbax® (Orbifloxacin) Oral Suspension from Merck Animal Health is a broad spectrum fluorquinolone indicated for skin infections in dogs and cats, and urinary tract infections in dogs. With patented ‘Taste Masking Technology’, dosing has never been easier. It's once-a-day dosing is convenient for pet owners to administer.
Tasty malt flavor accepted by 95% of cats & 96% of dogs 1, 2 Ready to use, no refrigeration required And, a patented ‘taste-masking’ ion exchange agent enables orbifloxacin to pass by an animal’s taste buds undetected direct to the stomach. Quinolones have been shown to cause arthropathy in immature animals. In animals with known or suspected CNS disorders, quinolones have been associated with CNS stimulation, which may lead to convulsive seizures. The use of fluoroquinolones in cats has been reported to adversely affect the retina and should be used with caution in cats. See Package Insert for full information including side effects, precautions, warnings and contraindications.
References: 1 Data on File. Multi-clinic, randomized, controlled field trial evaluating the use of Orbax® (Orbifloxacin) Oral Suspension and Synulox® (amoxicillin/clavulanate) in the treatment of cats with skin and soft tissue infections (primarily post-traumatic wounds and abscesses) in France, Belgium, and Germany in 2001. Madison, NJ: Intervet Inc. 2 Freedom of Information Summary. Original New Animal Drug Application (NADA 141-305). ORBAX® Oral Suspension. Roseland, NJ: Intervet Inc. July 1, 2009.